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Abstract  
We investigated bone regeneration in the femoral neck canal of osteoporotic rats using a 
novel animal model. We used a calcium sulphate (CS)/ Hydroxyapatite (HA) carrier to 
locally deliver a bisphosphonate, zoledronic acid (ZA), with or without added recombinant 
human bone morphogenic protein-2 (rhBMP-2). Ovariectomized Sprague-Dawley rats of 
28 weeks age were used.  A 1 mm diameter and 8 mm long defect was created in the 
femoral neck by drilling from the lateral cortex in the axis of the femoral neck leaving the 
surrounding cortex intact. Three treatment groups and one control group were used 1) 
CS/HA alone, 2) CS/HA+ ZA (10 μg) 3) CS/HA+ZA (10 μg)+rhBMP-2 (4 μg) and 4) Empty 
defect. The bone formation was assessed at 4 weeks post-surgery using in vivo micro 
computed tomography (micro-CT). At 8 weeks post-surgery, the animals were sacrificed 
and both defect and contralateral femurs were subjected to micro-CT, mechanical testing 
and histology. Micro-CT results showed that the combination of CS/HA with ZA or 
ZA+rhBMP-2 increased the bone formation in the defect when compared to the other 
groups and to the contralateral hips. Evidence of new dense bone formation in CS/HA+ZA 
and CS/HA+ZA+rhBMP-2 groups was seen histologically. Mechanical testing results showed 
no differences in the load to fracture between the treatments in either of the treated or 
contralateral legs. The CS/HA biomaterial can be used as a carrier for ZA and rhBMP-2 to 
regenerate bone in the femoral neck canal of osteoporotic rats.  
 
Keywords: Osteoporosis, Bisphosphonates, Bone Morphogenic Protein-2, Bone 
Regeneration, Femoral Neck, Ceramics  
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1. Introduction 
Osteoporosis and fragility fractures are increasing with age and only partly halted 
by primary and secondary national prevention programs (1). More than 8.9 million 
osteoporotic fractures occur annually worldwide, with approximately one third in Europe 
(2). The direct cost of managing osteoporosis was estimated at €37 billion, but if quality-
adjusted life-years (QALYs) lost was considered, the overall cost amounted to €98 billion in 
Europe in 2010 (2). Due to the aging population, fragility fractures are predicted to 
increase further in the next decade (2). The life expectancy in hip fracture patients 
decreases by nearly 25% when compared to age and gender matched populations (3). One 
fifth of all fragility fractures occurs in the hip with an almost equal ratio in the cervical and 
trochanteric region (2). 
Primary and secondary prevention methods evaluated for osteoporosis include 
calcium and vitamin D supplements, bisphosphonates, parathyroid hormone (PTH) and its 
analogues, and biological drugs targeting resorption (Denosumab, anti-RANKL) (4). 
Zoledronic acid (ZA) is a bisphosphonate and has been shown to reduce the risk of hip 
fracture by 41% in post-menopausal women (5). However, systemic usage of ZA is 
reported to have side effects, including myalgia (6) and osteonecrosis of the jaw with 
prolonged use (7). The interest in osteoporosis therapy is declining, in particular for 
secondary fracture prevention where the risk of subsequent hip fractures following a first 
fracture is high (8). This is to some extent based on reports of long term adverse effects 
with systemic bisphosphonates causing atypical fractures and lack of patient adherence to 
taking bisphosphonates, with half of patients stopping treatment during the first year (9). 
Thus, there is a need for novel preventive treatment modalities especially as major 
osteoporotic fractures per se are linked to increased mortality (3). 
Bone morphogenic protein-2 (BMP-2), induces osteogenic differentiation of 
mesenchymal cells and pre-osteoblasts into mature osteoblasts (10, 11).  Several studies 
indicate that a sustained and controlled release of BMP-2 over a longer period of time is 
required for optimal bone regeneration (12). The currently approved carriers for local 
delivery of rhBMP-2 provide only a burst release (13). Moreover, rhBMP-2 induces 
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premature bone resorption by also stimulating osteoclasts (14, 15), which in turn can be 
controlled by co-delivery of ZA (11, 16, 17). To investigate this approach, our group has 
developed an injectable calcium sulphate/hydroxyapatite (CS/HA) based biomaterial, 
which has been approved for clinical use in Europe (18, 19). The powder phase of the 
CS/HA biomaterial is premixed at a ratio of 60/40 (CS/HA) by weight.  The powder is mixed 
with a liquid phase consisting of an iodine-based contrast agent to allow radiographic 
visualization. After mixing with an aqueous solution, the calcium sulphate hemi-hydrate 
particles change state to the dihydrate causing the biomaterial to set into a hard mass, 
wherein hydroxyapatite particles are embedded in the composite material. The calcium 
sulphate phase dissolves in less than 2 months (20) leaving behind a porous 
osteoconductive matrix of hydroxyapatite as a scaffold for bone cells to grow on. In a 
previous study, local co-delivery of rhBMP-2 and ZA using the CS/HA biomaterial as carrier, 
led to a significant increase in bone formation in an abdominal muscle pouch model when 
compared to BMP-2 only group (16). Other studies have shown that when ZA was added to 
the carrier in a tibia defect model in rats, more newly-formed bone remained within the 
defect compared to when the material was used alone (21, 22).   
 In this study, we created a novel animal model to study the process of bone 
regeneration in the femoral neck canal in osteoporotic rats. Secondly, we investigated 
whether a CS/HA carrier delivering ZA or a combination of ZA and rhBMP-2 can improve 
bone regeneration in the femoral neck of osteoporotic rats with the long-term goal of 
preventing future osteoporotic fractures. We hypothesized that:  
 1. HA will provide an osteoconductive scaffold for bone formation and controlled 
delivery of both rhBMP-2 and ZA by interacting with them,  
2. The fast resorbing CS would increase scaffold osteoconductivity and provide release 
of unbound rhBMP-2 and ZA,  
3. rhBMP-2 will lead to differentiation and proliferation of progenitor cells and  
4. ZA can counteract premature bone resorption, leading to increased net bone 
formation.  
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2. Methods 
2.1 Sample preparation and experimental groups 
Animals were randomly allocated to the following groups (n=12/group): 1) CS/HA (CS/HA 
in the ratio of 60:40 w/w), 2) CS/HA+ZA (10 g), 3) CS/HA+ZA (10 g) + rhBMP-2 (4 g) and 
4) Empty defect (drilled but no filling). For the CS/HA group, the ceramic components were 
mixed without the addition of any bone active molecules. All animals with CS/HA 
treatment received 116 mg of the CS/HA powder and the liquid to powder ratio remained 
unchanged (0.43 mL to 1 g powder). The addition of ZA and rhBMP-2 was performed by 
adding a known amount of ZA solution or the combination of ZA and rhBMP-2 solution to 
the ceramic powder, followed by rigorous mixing. The doses of rhBMP-2 and ZA were 
chosen based on a previous study using the CS/HA biomaterial (22). After mixing, the 
material was transferred into a 1 mL graded syringe. Equal portions of the sterile paste 
were delivered onto a sterile dish and each portion was impacted into one animal thereby 
controlling the amount of the CS/HA biomaterial and respective drugs. The biomaterial 
was allowed to reach a suitable viscosity for impaction before implantation to allow for 
complete filling of the defect without any backflow of the material.  
 
2.2 Animal model and surgical procedure 
We used ovariectomized female Sprague-Dawley rats of 28 weeks age at surgery with an 
average weight of 442±29 g. Ovariectomy was performed at 12 weeks of age (Janvier Labs, 
France). The animals were left for 16 weeks to develop osteoporosis based on a previous 
study (23). Animals were anaesthetized using an intraperitoneal injection of Ketamine (90 
mg/kg, Apoteket AB, Sweden) and Xylazine (9 mg/kg, Apoteket AB, Sweden). An intra 
muscular injection of antibiotic solution (Streptocillin Vet, Apoteket AB, Sweden) was also 
given pre-operation. The right leg was shaved and disinfected and a 1.5 cm straight 
posterolateral incision made along the greater trochanter. The muscles were bluntly 
dissected and the leg internally rotated until the posterior short rotators were exposed. 
Tenotomy of the short rotators was performed and the posterior capsule was reached for 
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visualization but left intact. A 1 mm drill was used to create a critical defect in the femoral 
neck canal without fluoroscopic guidance, with the entry point behind the crest of the 
greater trochanter towards the superior-lateral part of the femoral head (Fig. 1). Drilling 
was stopped at the base of the sub-capital zone, producing a defect depth of 
approximately 8 mm (Fig. 1). At this point, the material based on each treatment group 
mentioned above, were impacted into the femoral canal using a 1 mm mandrel until the 
whole canal was filled with the material. Filling was made in a similar fashion in all animals. 
The left leg was left intact and used as a paired control. After wound closure, a single 
subcutaneous injection of buprenorphine (0.04 mg/kg) (Temegesic®, Apoteket AB, 
Sweden) was given post-surgery for pain control.  
To establish the degree of osteoporosis another 3 SHAM operated and 4 OVX animals were 
used as controls with no defect created in the femoral neck canal. SHAM animals 
underwent a bilateral skin incision in the lower abdomen at the age of 12-weeks but no 
ovariectomies were made. The OVX animals had their ovaries removed at 12-weeks.  The 
animals (3 SHAM and 4 OVX) were sacrificed at the same time as the experimental 
animals. The proximal tibiae were subjected to micro-CT and the trabecular bone analysis 
was performed approximately 1.5 mm distal to the tibial growth plate with a region of 
interest extending 150 slices distally (2.25 mm in total). 
2.3 In vivo micro-CT at 4 weeks  
The animals were anesthetized using a mixture of isoflurane (4%), oxygen and nitrous 
oxide at a flow rate of 0.4 L/min. Once asleep, the animals were moved to an animal 
holder of the micro-CT scanner (NanoScan, Mediso Medical Imaging Systems, Budapest, 
Hungary) and the isoflurane was reduced to 2%. Circular micro-CT scans were taken with 
480 projections and Medium zoom at 65 kV voltage and 1300 ms exposure time and the 
images were post-reconstructed to a voxel size of 20 m. Micro-CT imaging at the 4-week 
time point was performed only on the defect side.  
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2.4 Sacrifice and femur harvesting at 8 weeks 
The animals were sacrificed using carbon dioxide asphyxiation 8 weeks post-surgery. Both 
femurs (defect side and contralateral) were harvested, wrapped in saline soaked gauze 
and placed in 5 mL Eppendorf tubes. All analyses were performed on both the defect and 
contralateral legs. Freshly harvested specimens were subjected to micro-CT and thereafter 
frozen at -20 C until biomechanical testing.  
2.5 Ex vivo micro-CT at 8 weeks  
The samples in CS/HA group (n=11) and the other groups (n=12) were scanned at an 
operating voltage of 65 kV, exposure time of 1300 ms, maximum zoom with 480 
projections in circular scan mode using a NanoScan micro-CT scanner (Mediso Medical 
Imaging Systems, Budapest, Hungary). The images were post-reconstructed to a voxel size 
of 10 m.  
2.6 Micro-CT image processing and analysis  
All images from the 4 and 8 week time points were analyzed according to the same 
protocol. Images were post-reconstructed using Nucline software (inviCRO, Boston, MA) 
using a RAMLAK filter with a 100% cut-off. Images were realigned using Data Viewer (v.1.4, 
Skyscan, Belgium) to obtain a straight rectangular defect in the sagittal and coronal views. 
Trans-axial slices revealed a circular defect starting from the base of the sub-capital zone 
down to the point of entry in the femur. The analysis was performed on the trans-axial 
slices using CTAn (v.1.9.1.0 Skyscan, Belgium) and two different ROIs were used (Fig. 2). In 
both ROI 1 and ROI 2, the diameter of the ROI was 1 mm, corresponding to the diameter of 
the drill bit. ROI 1 contained the entire defect, starting at the base of the sub-capital zone 
to the point of entry in the posterior-cortex. The defect depth was 5 mm, which is less 
than the original defect, to exclude the cortical bone at the point of entry and any 
remaining old trabecular bone near the sub-capital zone. ROI 2 contained only the femoral 
neck canal region, which started at the base of the sub-capital zone to the end of the 
femoral neck canal (depth 3.4 mm). Images were thresholded using a lower gray scale 
value of 90 and an upper gray scale value of 255. This means that both bone and some 
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remnants of the CS/HA material were identified as mineralized tissue. Mineralized 
volume/tissue volume (MV/TV %) was used as the primary outcome variable of the micro-
CT analysis. The in vivo and ex vivo scans were performed using different imaging 
protocols, which were optimized for each condition. Thus, a direct comparison of MV/TV% 
at 4 and 8 weeks was not possible.  
2.7 Ex-vivo biomechanical testing of the femoral neck  
The bones were thawed at room temperature before performing the biomechanical 
testing and care was taken to keep the samples moist until testing. All bone samples for 
mechanical testing (n=9/group) were cut at the mid-diaphysis to ensure a stable grip 
during the testing. The bone specimen was kept in position using a cylindrical holding 
device mounted on an adjustable stage in order to achieve a femoral shaft angle of 9° with 
the vertical plane as described by Hessle et al. (24). Using a mechanical testing machine 
(Instron ® 8511.20 biaxial load frame connected to a MTS FlexTest 40 Controller, MTS 
TestSuite Multipurpose Elite Software) and a 250 N load cell, the femoral head was loaded 
using a flat end indentation device at a displacement rate of 1 mm s-1 until the fracture 
occurred. The experimental setup is shown in supplementary figure 1. The peak load to 
fracture was recorded for each specimen and compared between the groups as well as to 
the contralateral side. Moreover, the ratio of the peak force between the defect leg and 
contralateral leg was calculated. The location of the fracture site (lateral vs sub-capital) 
was also noted. 
2.8 Qualitative histology 
Bone specimens (n=2/group) that were not mechanically tested were thawed to room 
temperature and fixed in neutral buffered formalin overnight followed by decalcification 
using ethylenediaminetetraacetic acid (EDTA) (10% w/v, pH 7.2) for 4 weeks. Post 
decalcification, specimens were dehydrated and infiltrated with paraffin overnight. Finally, 
the specimens were embedded in paraffin and cooled at 4 C overnight before sectioning. 
All specimens were cut using a microtome (Thermo Scientific, USA) to a thickness of 5 m. 
Slides were deparaffinized, rehydrated and stained with hematoxylin and eosin (H&E) 
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using standard staining techniques. The stained slides were scanned on a high-resolution 
slide scanner (Hamamatsu, Japan) before analysis.  
2.9 Animal ethics statement 
All animal experimentation was approved by the Swedish Board of Agriculture (Animal 
ethics permit number: M 128-16). Animals had free access to food pellets and drinking 
water.  
2.10 Statistics  
SPSS (IBM SPSS Statistics for MacOS, V. 24, IBM Corp., NY, USA) was used for statistical 
analysis. Distribution of data were tested using the Shapiro-Wilk test (on residues) and by 
looking at the spread of the data. Normally distributed data were tested using ANOVA. 
Homogeneity of variances were tested using Levene’s test and in the case of non-
homogenous variances, ANOVA with Games Howell post-hoc test was used while 
homogenous variance data sets were analyzed using ANOVA with Tukey HSD post-hoc test. 
Non-normally distributed data were analyzed using independent samples Kruskal Wallis 
test for multiple groups. All paired analysis was performed using the Wilcoxon signed rank 
test.  
3.0 Results 
Microstructural analysis of the bone in the proximal tibial metaphysis comparing 
unoperated SHAM vs. OVX animals confirmed significant bone loss in the ovariectomized 
animals (Supplementary table 1). Postoperative radiographs showed no complications in 
any of the animals. One animal in the CS/HA group died at the 4 week micro-CT imagining 
session due to anesthesia complication. One sample from CS/HA+ZA group was excluded 
from the 4 week micro-CT analysis due to movement artefacts during the in vivo scans. 
During the 8-week micro-CT analysis, one sample each from Empty and CS/HA+ZA group 
were excluded due to artefacts during imaging. Initially n=9/group were used for 
mechanical testing but one sample in each of Empty, CS/HA and CS/HA+ZA+rhBMP-2 
group had to be excluded due to fractures occurring in the femoral neck canal during the 
adjustment of the compression device. Thus, the sample sizes for the biomechanical 
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testing were n=8 for Empty, CS/HA and CS/HA+ZA+rhBMP-2 groups and n=9 for CS/HA+ZA 
group.  
3.1 In vivo micro-CT at 4 weeks 
In ROI 1 i.e. the entire drilled region, the MV/TV in all CS/HA treated groups was higher 
than in the empty group (p<0.001) (Fig. 3A). The MV/TV in the CS/HA+ZA group was also 
higher than in the CS/HA group (p<0.01). No differences were seen in the MV/TV between 
the CS/HA and CS/HA+ZA+rhBMP-2 groups. Furthermore, no differences were observed 
between the CS/HA+ZA and CS/HA+ZA+rhBMP-2 group. Similar results were seen in ROI 2 
(femoral neck canal) with the only difference of the CS/HA+ZA+rhBMP-2 group being 
higher than the CS/HA group (Fig. 3B) (p<0.05).  
3.2 Ex vivo micro-CT at 8 weeks 
For ROI 1, the MV/TV was higher in the CS/HA group (p<0.05), CS/HA+ZA group and 
CS/HA+ZA+rhBMP-2 group (p<0.001) compared to the empty group (Fig. 4A). Both 
CS/HA+ZA and CS/HA+ZA+rhBMP-2 group had significantly higher MV/TV compared to the 
CS/HA group (p<0.001). No significant differences were seen between the CS/HA+ZA and 
CS/HA+ZA+rhBMP-2 groups. In ROI 2, no differences were seen in MV/TV between the 
empty group and the CS/HA group (Fig. 4B). The MV/TV in both CS/HA+ZA and 
CS/HA+ZA+rhBMP-2 groups was higher than both in the empty and the CS/HA group 
(p<0.001). Similar to ROI 1, no significant differences in the MV/TV% was seen between 
the CS/HA+ZA group and CS/HA+ZA+rhBMP-2 group.  
Irrespective of the treatment on the defect side, no significant differences in MV/TV was 
seen in the contralateral leg in ROI 1 or ROI 2 (Table 1).  
When comparing the defect leg to the contralateral leg, the MV/TV in both ROI 1 and ROI 2 
was significantly lower in the defect leg of the empty group (p<0.05) (Table 1). No changes 
in the MV/TV in either ROI 1 and ROI 2 was seen between the defect and the contralateral 
legs when CS/HA was implanted (Table 1). The MV/TV of CS/HA+ZA group and 
CS/HA+ZA+rhBMP-2 group in the defect leg was higher than their respective contralateral 
legs (p<0.01) for both ROI 1 and ROI 2 (Table 1). 
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3.3 Ex-vivo biomechanical testing of the femoral neck 
No difference was found in the peak force to fracture in the biomechanical testing for 
either the defect or contralateral control legs (Fig. 5). However, when a paired analysis 
between the defect and contralateral controls was performed, the defect leg in the CS/HA 
group had significantly lower average peak force to fracture (p<0.05) (Table 1). In all other 
groups, no significant differences in the peak force to fracture between defect and 
contralateral legs could be observed (Table 1).  
3.4 Location of fracture 
Fractures were classified as lateral or sub-capital and a description of fracture location for 
each treatment group is provided in Fig. 6.  
3.5 Qualitative histology 
The empty group showed no signs of bone formation in the defect region i.e. neither in the 
femoral neck canal region nor in the femoral region (Fig. 7A-C). In CS/HA treated group 
(Fig. 7D-F), small amounts of new bone could be seen in the femoral neck canal (Fig. 7E). 
However, it was noted that the material had migrated towards the femoral region, as seen 
by hydroxyapatite crystals in the medullary canal (Fig. 7F). Signs of new bone formation 
were more pronounced in this region. In both the CS/HA+ZA (Fig. 7G-I) and 
CS/HA+ZA+rhBMP-2 (Fig. 7J-L) groups, more new bone could be seen both in the femoral 
neck canal and towards the femoral region. In many areas, bone could be seen growing 
around the hydroxyapatite particles. Furthermore, remnants of the material could also be 
seen in both cases. The bone formed in the CS/HA+ZA+rhBMP-2 group appeared to be 
more remodeled, characterized by the presence of more remodeled and less compact 
trabecular islands throughout the defect area. Contrary to this, the bone formed in the 
CS/HA+ZA groups was more densely organized. 
4. Discussion 
In this study, we evaluated bone formation in a novel femoral neck model of bone 
regeneration following implantation of an injectable bio ceramic using ovariectomized rats 
to mimic post-menopausal osteoporosis. In osteoporosis, the femoral neck is of the 
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highest clinical interest for local bone augmentation and fracture prevention. Several 
studies have demonstrated the effect of ovariectomy (OVX) on bone loss at various 
anatomical sites in rats (23, 25, 26). The Food and Drug Administration has also approved 
the OVX rat model as a model to study both pharmacological and material testing for 
osteoporosis. The strain, age at OVX and age at surgery, affecting trabecular bone loss, 
were chosen based on a previously published study by Li et al., who performed OVX on 3 
month old Sprague Dawley rats. A significant reduction in the amount of trabecular bone 
was reported 90 days post OVX, reaching a plateau at approximately 9 months post OVX 
(23). The effect of OVX on the cortical bone was noted only first after a year post OVX. The 
surgical protocol described in this study has not been used before in OVX rats, however, a 
similar model has been reported earlier in an osteoporotic model of cynomolgus monkeys 
(27). Seeherman et al. injected calcium phosphate biomaterial intraosseously with or 
without rhBMP-2 (0.75 mg/animal) into the femoral neck of OVX monkeys and 
demonstrated an increase in trabecular volume, cortical thickness as well as in the 
maximum bending force in the femoral neck 6 months post-operation, the maximum 
duration of their study (27).  
In vivo micro-CT results at 4 weeks showed a significant increase in the MV/TV of 
all CS/HA treated groups when compared to the empty group. However, the inter group 
differences in the CS/HA treatment, irrespective of the bioactive factor added, were less 
than the differences at 8 weeks, which could be attributed to the high density of the 
biomaterial, interfering with the micro-CT quantifications at 4 weeks. An earlier study of 
the degradation of the CS/HA biomaterial in an ectopic muscle pouch model showed that 
the CS phase takes around 6 weeks to resorb while the hydroxyapatite remained through 
the 8 weeks of the study (20). This slow degradation of the material during the initial 4 
weeks might explain the small differences between the MV/TV in all the CS/HA treated 
groups at 4 weeks. At 8 weeks, when all CS phase has been resorbed, the difference in the 
MV/TV in CS/HA groups increased. The addition of CS/HA in the defect led to a significant 
increase in MV/TV% in ROI 1 compared to the empty group (p<0.05). The choice of 
augmenting the CS/HA biomaterial with rhBMP-2 and ZA was obvious due to 
osteoinductive properties of rhBMP-2 and anti-resorptive properties of ZA. Both molecules 
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have been extensively used in pre-clinical models mimicking osteoporosis (28-30). 
Mathavan and co-workers recently showed that using BMP-7 in an osteoporotic rat 
femoral osteotomy model, a 100% union rate was achieved as compared to 56% in non-
treated control rats. This study also demonstrated a slightly increased effect of BMP-7 in 
osteoporotic animals compared to the non-osteoporotic rats (29). Similarly, Gao et al., 
used hydroxyapatite coated titanium implant with a surface coating of ZA in the tibiae of 
OVX rats. They found that approximately 8 times higher push-out force was required for 
implants in the ZA treated group when compared to the non-treated group (30).  
The results from the 8 weeks micro-CT experiments corroborate well with the 
published results. The addition of rhBMP-2 and ZA increased MV/TV in both defect ROIs 
significantly when compared to the empty and the CS/HA group alone. Also, noteworthy is 
that the micro-CT results between the CS/HA+ZA and the CS/HA+ZA+rhBMP-2 did not 
show any significant differences. This suggests that controlled and local delivery of ZA 
alone in a bony environment may lead to significant bone formation. This is a debatable 
finding and while some in vitro studies have suggested ZA at very low concentrations can 
induce osteogenic differentiation of mesenchymal stem cells (MSCs) (31), others described 
ZA inducing apoptosis in human osteosarcoma cells, MG-63 (32). Recent studies have 
shown a positive effect by local delivery of ZA alone in a bone defect in vivo (21, 22, 30). 
Whether these effects are only anti-catabolic, meaning that ZA prevents resorption of 
bone that would form irrespective of treatment with a bioactive molecule or if 
endogenous growth factors including BMPs act synergistically with ZA is unknown. Further 
mechanistic studies are required to establish the ability of ZA to cause increased net bone 
formation.  
An important aspect of this study was to ensure the local delivery of both ZA and 
rhBMP-2. Our aim was to circumvent the side effects of systemic administration of ZA and 
targeted spatiotemporal delivery of rhBMP-2, respectively. Different polymeric systems have 
been used for this task (11, 33), however, the non-injectability of these materials requires 
invasive surgical methods. The CS/HA biomaterial provides an injectable platform for delivery 
of both bioactive molecules and with a minimally invasive approach. The comparisons from 
the micro-CT and biomechanical testing of the contralateral sides clearly indicated that none 
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of the treatments has a systemic effect on the contralateral femur, which is a major goal of 
local delivery. Furthermore, paired analysis of MV/TV of the CS/HA+ZA and CS/HA+ZA+rhBMP-
2 groups showed a significant increase in the defect leg compared to the contralateral leg, 
which emphasizes the efficacy of local delivery in this model. One might argue that the MV/TV 
is not an accurate measure of bone formation when the bone has been treated with a 
radiopaque biomaterial such as CS/HA. However, representative histology from the CS/HA+ZA 
and CS/HA+ZA+rhBMP-2 groups confirmed abundant amounts of regenerated viable 
trabecular bone in the femoral neck canal region as well as in the trochanteric region (Fig. 7), 
thereby strengthening the micro-CT quantifications.  
As an indirect translation of significant bone regeneration in the femoral canal of 
CS/HA+ZA and CS/HA+ZA+rhBMP-2 treated animals, one would also expect an increased 
mechanical strength. However, the biomechanical testing did not show significant 
differences between any of the treatment groups on either of the legs. We used a 
mechanical testing protocol described earlier by Hessle et al. (24). In our study, we created a 
critical size trabecular bone defect in the femoral neck (34). We speculate that most of the 
compressive mechanical strength (>90%) of the femoral neck in humans is provided by the 
cortical bone, whereas the trabecular bone contributes only <10% (34). The trabecular bone 
contributes more to the shear strength, which is not tested in the current compression 
testing setup. The femoral neck and the intertrochanteric region have a larger proportion of 
trabecular bone than the subtrochanteric region, and the trabecular bone is generally 
weaker than the cortical bone. Another important aspect to emphasize is the age of the 
animals used in this study. Li and co-workers followed the development of osteopenia-like 
features in the proximal femur of OVX rats over one year and only noticed a significant 
reduction in the cortical width after the one year time point (23). In our study, we waited 
only 16 weeks post OVX and one can assume that the progression of cortical thinning at this 
time point is negligible compared to the non-OVX rats. Potentially, the biological need to 
guide cortical regeneration in an already healthy cortex at this time point is absent from a 
bone homeostasis perspective. Whether a longer follow-up post-surgery, older age at OVX 
or a different mechanical testing protocol would change the biomechanical results are only 
speculative at the moment and further experiments will be required to verify these. 
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The absence of a systemic ZA group is a limitation of the study, since such a group 
could potentially have illuminated the role of local delivery of ZA in this animal model. 
Furthermore, we also did not use CS/HA+rhBMP-2 without ZA. However, based on our 
previous experience, we were confident about the efficacy of local ZA delivery using the 
CS/HA biomaterial (16, 22). These studies also indicated that the CS/HA biomaterial 
produces significantly higher volume of bone when combined with both rhBMP-2 and ZA  
compared to only rhBMP-2 and thus we reduced the number of experimental animals 
based on the guidelines of the 3R’s Principle (35). The age of the animals at OVX as well as 
the time to wait post OVX might be considered to be rather premature and other studies 
have suggested different ages (23, 25, 36). We chose the age most likely to induce 
osteoporosis-like characteristics in the trabecular bone of the proximal femur of rats 
reported earlier (23). Also, we were interested in trabecular bone regeneration in this 
model and slightly younger rats would have possessed more responsive stem/progenitor 
cells compared to older rats (37). The quantitative results in this study are based on micro-
CT imaging but it is important to keep in mind that separating new bone formation and 
ceramic biomaterial remnants is very challenging. Due to this reason, the results present 
quantifications of bone/material composite with a high density. Despite this, the 
representative histology findings support the micro-CT findings well.  Further, our study 
failed to show whether the bioavailability of local ZA and rhBMP-2 is only early on or 
prolonged in this model. However, according to an ongoing study, we have confirmed 
strong interaction of ZA with the CS/HA biomaterial and a sustained release of rhBMP-2 
over a period of 4 weeks in-vivo. Based on these results, we speculate that ZA is locally 
available for a long period of time while rhBMP-2 could possibly have been released 
completely after 8 weeks (38). We were also not able to elucidate the mechanism of small 
amounts of released ZA re-uptake by surrounding bone or other skeletal sites in this study, 
though we did not see any significant effects on the contralateral side. 14C Radiolabeled ZA 
might be able to elucidate a complete pharmacodynamics of ZA from the CS/HA 
biomaterial when injected in the femoral neck canal. Finally, this study does not elucidate 
if the addition of ZA has any impact on CS/HA resorption for which long-term studies 
would be required.  
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5.0 Conclusions 
In conclusion, the model developed to study the process of bone regeneration in the 
femoral neck canal of OVX rats in this study is novel and promising for future research. The 
CS/HA biomaterial combined with ZA or both rhBMP-2 and ZA led to significantly enhanced 
bone regeneration in the femoral neck canal of osteoporotic rats in this model as seen 
from micro-CT and histology. CS/HA biomaterial alone was superior to the empty group in 
the entire defect region. Moreover, these results did not translate into an increased 
mechanical strength in the treated legs compared to the non-treated legs. Long-term 
studies with increased time post-OVX and possibly a new biomechanical testing protocol 
are required to establish whether this combination can be used as a preventive treatment 
for osteoporotic fractures.  
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Table 1: Micro-CT, biomechanical testing data and statistical analysis 
Treatment Groups 
Method Parameter Empty 
(A) 
 
 
 
 
CS/HA 
(B) 
 
 
 
 
CS/HA+ 
ZA (10 μg) 
(C) 
 
 
CS/HA+ 
ZA (10 μg)+ 
rhBMP-2 (4 μg) 
(D) 
 
Statistical Differences 
(Between Groups) 
Micro-CT 
(4-weeks) 
MV/TV (%) 
(ROI 1) 
Defect Leg 
5.1
(3.1- 
7.0 
n=12 
57
(49.1-
64.8) 
n=12 
77.4
(71.5-83.4)
 
n=11 
71 
(61.2-80.8) 
 
n=12 
B,C,D vs A 
*** 
C vs B **, 
D vs B ns 
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Micro-CT 
(8-weeks) 
MV/TV (%) 
(ROI 1) 
Defect Leg 
5.9 
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n=11 
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(11.4-
25.2) 
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(44.5-66) 
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C,D vs 
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C,D vs B 
*** 
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ANOVA 
G.Howell 
Post-hoc 
 
 
 
 
ADf vs ACl * 
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CDf vs CCl ** 
DDf vs DCl ** 
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Contralateral 
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statistically 
significant 
differences
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HSD 
MV/TV (%) 
(ROI 2) 
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A = Empty, B = CS/HA, C = CS/HA+ZA, D = CS/HA+ZA+rhBMP-2. The subscript Df indicates the defect leg and Cl is contralateral. Data in brackets 
represents the lower and upper bounds of the 95% confidence interval. Italicized numbers show the sample size for each evaluation method 
and each group. Statistical significance is set at: * p<0.05, **p<0.01,*** p<0.001. ns indicates non-significant differences. 
  
Contralateral 
Leg 
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25.4) 
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significant 
differences
HSD 
Mechanical 
Testing 
(8-weeks) 
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(117.7-
144.6) 
  n=8 
136 
(127-
144.9) 
n=8 
145.4 
(128.3-
162.5) 
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Multiple 
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Figure Legends 
 
Figure 1. Surgical procedure. (A) The exposed site of incision. (B) The bone being drilled at 
the crest of the femur using a posterior approach with the drill bit used to create the 
defect (inset). (C) The position of the drill bit after completion of the drilling and the black 
arrow points at the femoral head. (D) The point of entry in the cortical bone. (E) A piece of 
CS/HA biomaterial (black arrow) being impacted into the defect using a mandrel. Inset in 
(E) shows the mandrel used for impaction.  
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Figure 2. Micro-CT region of interest (ROI) selection for quantification. Top Panel shows 
the dimensions used for micro-CT analysis in ROI 1 while the bottom panel shows the 
dimensions used for ROI 2. The above image is only for representation and belongs to the 
empty group. 
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Figure 3. Micro-CT results from 4 weeks post-surgery. (A,B) show the MV/TV% in ROI 1 
and ROI 2, respectively from the in vivo scans at 4 weeks post-surgery. * indicates p<0.05, 
** indicates p<0.01 and *** indicates p<0.001. 
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Figure 4. Micro-CT results from 8 weeks post-surgery. (A,B) show the MV/TV% of the 
defect leg in ROI 1 and ROI 2, respectively, 8 weeks post-surgery. * indicates p<0.05, ** 
indicates p<0.01 and *** indicates p<0.001. 
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Figure 5. Biomechanical analysis 8 weeks post-surgery. (A,B) show the peak force to 
fracture in the defect leg and the contralateral leg, respectively, 8 weeks post-surgery. No 
statistically significant differences between the groups were found. 
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Figure 6. Biomechanical testing and location of fracture. Top panel shows fracture 
classification based on the location of the fracture. Table in the bottom panel shows the 
number of fractures of each type in different treatment groups and tested legs.  
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Figure 7. Representative histology 8 weeks post-surgery.  (A-C) show H&E stained 
specimen from the Empty group at low magnification (A), in the femoral neck canal (B) and 
in the femoral region (C), respectively. (D-F), (G-I) and (J-L) show H&E stained specimens 
from the CS/HA (D-F), CS/HA+ZA (G-I) and CS/HA+ZA+rhBMP-2 (J-L) groups, respectively. 
(D,G and J) show a low magnification overview of the samples while (E,H and K) show the 
bone formation in the femoral neck canal and (F,I and L) show the bone formation in the 
femoral region. * Indicates new bone formation and # indicates remnants of the CS/HA 
material in the form of hydroxyapatite particles.  
D
ow
nl
oa
de
d 
by
 G
LA
SG
O
W
 U
N
IV
ER
SI
TY
 L
IB
RA
RY
/S
w
et
s /
 8
81
35
88
8 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
6/
05
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 33 of 34 
 
 
 
33 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Ca
lci
um
 S
ul
ph
at
e/
Hy
dr
ox
ya
pa
tit
e 
Ca
rr
ie
r f
or
 B
on
e 
Fo
rm
at
io
n 
in
 th
e 
Fe
m
or
al
 N
ec
k 
of
 O
st
eo
po
ro
tic
 R
at
s (
DO
I: 
10
.1
08
9/
te
n.
TE
A.
20
18
.0
07
5)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
Supplementary table 1: Comparison of bone microstructural parameters in SHAM vs. OVX 
animals. 
 
  
 
 
Group 
Parameter 
BV/TV 
% 
Trabecular 
Number (Tb.N) 
1/mm 
Trabecular 
Separation (Tb.Sp) 
m 
Trabecular 
Thickness (Tb.Th)
m 
 
SHAM 
(n=3) 
17.2 ± 8.3 0.039 ± 0.015 16.5 ± 4.7 4.2 ± 0.6
 
OVX 
(n=4) 
4.0 ± 2.8 0.007 ± 0.005 67.0 ± 27.3 5.3 ± 0.3
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Supplementary Figure 1: Experimental setup for biomechanical testing. 
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